News Releases

-  Uliledlimab is a differentiated monoclonal antibody designed to target CD73 and promote stronger activation of patients' immune system against cancer cells. -  In newly diagnosed patients who were not eligib le for or declined chemotherapy treatment, 63% o f the patient s with CD73 High  and

GAITHERSBURG, Md. and SHANGHAI , May 1, 2023 /PRNewswire/ -- I-Mab (" I-Mab " or the "Company") (Nasdaq: IMAB ), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that it has filed its annual report on Form

GAITHERSBURG, Md. and SHANGHAI , April 26, 2023 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB ), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that a poster featuring the latest clinical data of

Award is an important victory for I-Mab and its shareholders on multiple levels, ending the multi-year long dispute Tribunal completely denied Tracon's groundless damages claim of over $200 million relating to I-Mab's next-generation bi-specific antibody assets and awarded no damages to Tracon

GAITHERSBURG, Md. and SHANGHAI , April 24, 2023 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB ), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the first patient in a Phase 3 registrational

Strategic reprioritization of the Company's pipeline to focus on key clinical assets and overall streamlining of corporate structure and workforce, resulting in a significant reduction in the cash burn rate and in significant pipeline achievements by focus Thirteen key clinical milestones achieved

GAITHERSBURG, Md. and SHANGHAI, China , March 20, 2023 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB ), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the Company will report financial results

In light of the recent development of the Silicon Valley Bank (the “SVB”), I-Mab (the “Company”) today issued a statement confirming that the Company does not hold any cash deposits at SVB or its affiliates, and has no exposure to or business dealings with SVB or its affiliates.

GAITHERSBURG, MD . and SHANGHAI , March 7, 2023 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB ), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that I-Mab has been granted "A" rating by MSCI (